The e-Learning Module is an important knowledge translation tool for the MAG-CP project. It is an interactive online tool for all health care providers. The e-learning module:
Summarizes the relevant evidence contained in the May 2011 SOGC Clinical Practice Guidelines on Magnesium Sulphate for fetal neuroprotection
- Includes questions and answers to test your knowledge
- Includes other reference material (such as other relevant guidelines) and practice tools (such as physician's orders, pharmacy orders, posters, pocket cards, etc)
- Provides maternal care providers on barriers to practice change, which we hope will stimulate relevant discussion at each institution.
The e-Learning Module uses the online REDCap platform, and presents the module in several parts. Once a section has been completed, an e-mail will be sent that contains a link to the next section of the module, though continuing the module can be done at any time. You can access the module by clicking here. Why not consider putting a link to the e-Learning Module on your hospital intranet?
After completing the e-Learning Module (including the pre-course survey, pre-test, post-test, and questions in the Discussion Forum), you can earn a Certificate of Completion for your CV by e-mailing the MAG-CP co-ordinator (CPN@cw.bc.ca). Please note that this module can be eligible for MAINPRO or MOCOMP CME credits as a Personal Learning Project (PLP). Details can be entered by signing onto MAINPORT. If you have any questions, please contact the co-ordinator.
SOGC Clinical Practice Guidelines
Access a copy of the SOGC Clinical Practice Guidelines on Magnesium Sulphate for Fetal Neuroprotection here.
Links to the abstracts of the four primary trials referenced in the SOGC Clinical Practice Guidelines for fetal neuroprotection can be found below.
Effect of magnesium sulfate given for neurorprotection before preterm birth: a randomized controlled trial.
Crowther CA, Hiler JE, Doyle LW et al. (JAMA 2003 Nov 26; 290(20):2669-76)
Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*.
Marret S, Marpeau L, Zupan-Simunek V et al. (BJOG 2007 Mar; 114(3):310-8)
Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.
Mittendorf R, Dambrosia J, Pryde PG et al. (Am J Obstet Gynecol 2002 Jun; 186(6):1111-8)
A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
Rouse DJ, Hirtz DG, Thom E et al. (N Engl J Med 2008 Aug 28;359(9):895-905)
Links to the abstracts of the three meta-analyses cited in the SOGC Clinical Pratice Guidlines for fetal neuroprotection can be found below:
Effects of Antenatal Exposure to Magnesium Sulfate on Neuroprotection and Mortality in Preterm Infants.
Constantine MM, Weiner SJ (Obstet Gynecol 2009 Aug;114(2 Pt 1):354-64)
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.
Conde-Agudelo A, Romero R (Am J Obstet Gynecol 2009 Jun;200(6):595-609)
Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
Doyle LW, Crowther CA, Middleton P et al. (Cochrane Database Syst Rev 2007 Jul 18;(3):CD004661)